Trial Profile
A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 1040 (Primary) ; Aspirin
- Indications Pulmonary embolism; Stroke
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 27 Feb 2020 Results evaluating the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects published in the Journal of Clinical Pharmacology
- 04 Mar 2014 New trial record